TY - JOUR T1 - Response to: Cryoglobulinemic vasculitis in the era of direct-acting antiviral drug JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e6 DO - 10.1136/annrheumdis-2016-210695 VL - 76 IS - 3 AU - David Saadoun AU - Patrice Cacoub Y1 - 2017/03/01 UR - http://ard.bmj.com/content/76/3/e6.abstract N2 - We thank Moiseev et al for their interest in our work regarding sofosbuvir and ribavirin in hepatitis C virus (HCV)-associated mixed cryoglobulinemia vasculitis (VASCUVALDIC study)1 and to bring new elements for discussion.Moiseev et al emphasise that treatment with immunomodulatory or immunosuppressive therapy (including rituximab) may have contributed to the impressive results of the VASCUVALDIC study. We have to stress that with the advent of new direct-acting antiviral (DAA) drugs (ie, sofosbuvir plus ribavirin), up to 87.5% of patients achieved complete clinical remission while only 17% of patients required the use of rituximab and glucocorticosteroids associated with antiviral therapy.1 In comparison, first-generation protease inhibitors … ER -